I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
The EU Chamber of Commerce in China has released its bi-annual “European Business in China...
Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products
Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against...
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk...
MicroPort Scientific Reports 19% Revenue Growth in H1 2023, Driven by Diverse Interventions
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its financial report for...
Amgen Launches Global Collaboration Network to Advance Oncology Research
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...
Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson
Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...
Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases
Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum...
Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit
Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced...
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...
Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment
US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...
WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications
The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...
Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...